Northwestern Mutual Wealth Management Co. Purchases New Position in Quest Diagnostics Incorporated $DGX

Posted by Brenda Bartman on Aug 24th, 2026

Northwestern Mutual Wealth Management Co. acquired a new position in shares of Quest Diagnostics Incorporated (NYSE:DGX – Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 26,801 shares of the medical research company’s stock, valued at approximately $5,681,000.

Several other institutional investors and hedge funds also recently made changes to their positions in DGX. Key Financial Inc increased its stake in shares of Quest Diagnostics by 1,728.6% during the first quarter. Key Financial Inc now owns 128 shares of the medical research company’s stock worth $25,000 after purchasing an additional 121 shares during the period. Quattro Advisors LLC bought a new stake in Quest Diagnostics in the 4th quarter valued at $25,000. DV Equities LLC bought a new stake in Quest Diagnostics in the 4th quarter valued at $27,000. Sittner & Nelson LLC bought a new stake in Quest Diagnostics in the 4th quarter valued at $29,000. Finally, McIlrath & Eck LLC acquired a new position in Quest Diagnostics in the 4th quarter valued at $32,000. Institutional investors and hedge funds own 88.06% of the company’s stock.

Insider Activity

In related news, SVP Mark E. Delaney sold 1,600 shares of the company’s stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $235.18, for a total transaction of $376,288.00. Following the completion of the sale, the senior vice president directly owned 10,335 shares in the company, valued at $2,430,585.30. This represents a 13.41% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO J. E. Davis sold 10,000 shares of the firm’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $194.14, for a total value of $1,941,400.00. Following the completion of the sale, the chief executive officer directly owned 132,423 shares in the company, valued at $25,708,601.22. This trade represents a 7.02% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 19,747 shares of company stock worth $3,947,088. Insiders own 0.88% of the company’s stock.

Quest Diagnostics Price Performance

Shares of NYSE:DGX opened at $244.34 on Monday. The firm has a 50 day moving average of $219.35 and a 200-day moving average of $205.29. Quest Diagnostics Incorporated has a 12 month low of $171.18 and a 12 month high of $245.68. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.72. The stock has a market capitalization of $26.97 billion, a PE ratio of 25.94, a PEG ratio of 2.25 and a beta of 0.56.

Quest Diagnostics (NYSE:DGX – Get Free Report) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $3.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.82 by $0.30. Quest Diagnostics had a net margin of 9.18% and a return on equity of 16.01%. The business had revenue of $3.04 billion for the quarter, compared to analyst estimates of $2.97 billion. During the same quarter last year, the business posted $2.62 EPS. The firm’s revenue for the quarter was up 10.2% on a year-over-year basis. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. On average, equities research analysts predict that Quest Diagnostics Incorporated will post 11.15 EPS for the current fiscal year.

Quest Diagnostics Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 21st. Stockholders of record on Tuesday, October 6th will be paid a $0.86 dividend. The ex-dividend date is Tuesday, October 6th. This represents a $3.44 annualized dividend and a dividend yield of 1.4%. Quest Diagnostics’s dividend payout ratio (DPR) is presently 36.52%.

Analyst Upgrades and Downgrades

DGX has been the topic of several recent research reports. Argus set a $260.00 price objective on Quest Diagnostics in a research report on Wednesday, July 29th. UBS Group upped their price target on shares of Quest Diagnostics from $220.00 to $232.00 and gave the company a “neutral” rating in a research note on Friday, July 24th. Truist Financial raised their price target on shares of Quest Diagnostics from $225.00 to $250.00 and gave the stock a “hold” rating in a research report on Friday, July 24th. Weiss Ratings upgraded shares of Quest Diagnostics from a “buy (b+)” rating to a “buy (a-)” rating in a research note on Wednesday, August 12th. Finally, Barclays increased their target price on shares of Quest Diagnostics from $230.00 to $250.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and seven have given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $235.31.

Check Out Our Latest Research Report on DGX

Quest Diagnostics Profile

(Free Report)

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.